SlideShare uma empresa Scribd logo
1 de 1
Result Content View                                                                                              Page 1 of 1


       [48] Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or
       weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American
       Breast Cancer Intergroup Trial E1199.

       Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE.
       From the Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG), Cancer and Acute
       Leukemia Group B (CALBG), and the North Central Cancer Treatment Group (NCCTG)

       Purpose: To compare the effectiveness of adjuvant paclitaxel with docetaxel, and the effectiveness of every 3 week with
       weekly adjuvant taxane therapy in patients with operable breast cancer.
       Methods: Eligibility criteria included axillary lymph node positive or high-risk (tumor at least 2 cm) node-negative breast
       cancer. All patients received 4 cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) every 3 weeks,
       followed by either: (1) paclitaxel 175 mg/m2 every 3 weeks x 4 (P3), (2) paclitaxel 80 mg/m2 weekly x 12 (P1), (3)
       docetaxel 100 mg/m2 every 3 weeks x 4 (D3), or (4) docetaxel 35 mg/m2 weekly x 12 (D1). All patients with estrogen
       and/or progesterone receptor (ER/PR)-positive disease received a 5 year or longer course of adjuvant hormonal therapy,
       consisting either of tamoxifen (20 mg daily), an aromatase inhibitor (AI; for post-menopausal women beginning in 2003 at
       the discretion of the treating physician), or tamoxifen followed by an AI. The primary comparisons included taxane (P vs. D)
       and schedule (every 3 weeks vs. weekly). The trial had 86% power to detect a 17.5% reduction in failure for either primary
       comparison. The primary endpoint was disease-free survival (DFS), defined as local, regional, and/or distant relapse,
       second primary breast cancer, or death without recurrence.
       Results: A total of 4988 eligible patients were accrued between October 1999 and January 2002. The ECOG Data
       Monitoring Committee advised release of the data after 856 DFS events (82% of total information) occurred after a median
       follow-up was 46.5 months at the fourth planned interim analysis, including the following number of DFS events (and
       relapses) for each arm: P3-230 (197), P1-195 (168), D3-206 (163), D1-225 (185). For the primary analyses, there were no
       significant differences in the hazard ratios (HR) comparing taxane (0.985; p=0.83) or schedule (1.043; p=0.54) for DFS,
       and it is unlikely that either comparison could become significant after full planned information is obtained. When
       comparing the standard arm (P3) to the other arms (with a HR > 1 favoring the experimental arms), the HRs were 1.20
       (95% confidence intervals [CI] 0.99, 1.46; p = 0.06) for arm P1, 1.13 (95% CI 0.94, 1.36; p=0.20) for arm D3, and 1.03
       (95% CI 0.85, 1.23; p=0.78) for arm D1. The incidence of worst grade toxicity (grade 3/4) was 24%/6% for arm P3, 24%/4%
       for arm P1, 21%50% for arm D3, and 39%/6% for arm D1.
       Conclusions: There were no differences in DFS when comparing taxane or schedule, the primary study endpoints. There
       was a trend toward improved DFS associated with weekly paclitaxel compared with the standard treatment arm.

       Thursday, December 8, 2005 3:30 PM

       General Session 2 (1:30 PM-3:30 PM)




                                                              Close Window




      http://www.abstracts2view.com/sabcs05/view.php?nu=SABCS05L_2020                                                     1/4/2006
PDF created with FinePrint pdfFactory Pro trial version www.pdffactory.com

Mais conteúdo relacionado

Mais procurados

Сравнение эффективности препаратов Карбоплатин (Carboplatin) и Паклитаксел (P...
Сравнение эффективности препаратов Карбоплатин (Carboplatin) и Паклитаксел (P...Сравнение эффективности препаратов Карбоплатин (Carboplatin) и Паклитаксел (P...
Сравнение эффективности препаратов Карбоплатин (Carboplatin) и Паклитаксел (P...oncoportal.net
 
Epidemological methods
Epidemological methodsEpidemological methods
Epidemological methodsKundan Singh
 
Metformin and cancer journal club
Metformin and cancer  journal clubMetformin and cancer  journal club
Metformin and cancer journal clubmadurai
 
REIRRADIATION FOR BRAIN TUMORS
REIRRADIATION FOR BRAIN TUMORSREIRRADIATION FOR BRAIN TUMORS
REIRRADIATION FOR BRAIN TUMORSKanhu Charan
 
Discuss the principles guiding the use of radiotherapy in surgery
Discuss the principles guiding the use of radiotherapy in surgeryDiscuss the principles guiding the use of radiotherapy in surgery
Discuss the principles guiding the use of radiotherapy in surgeryAbdullahi Sanusi
 
Managing Oligometastatic Lung Cancer
Managing Oligometastatic Lung CancerManaging Oligometastatic Lung Cancer
Managing Oligometastatic Lung CancerChoice Cancer Care
 
Umbrella, Basket and Platform trials
Umbrella, Basket and Platform trialsUmbrella, Basket and Platform trials
Umbrella, Basket and Platform trialsGovindMishra61
 
Innovative clinical trial designs
Innovative clinical trial designs Innovative clinical trial designs
Innovative clinical trial designs Emad Shash
 
Personalized Medicine in Oncology
Personalized Medicine in OncologyPersonalized Medicine in Oncology
Personalized Medicine in OncologyBita Fakhri
 
Personalized Medicine in Diagnosis and Treatment of Cancer
Personalized Medicine in Diagnosis and Treatment of Cancer Personalized Medicine in Diagnosis and Treatment of Cancer
Personalized Medicine in Diagnosis and Treatment of Cancer Maryam Rafati
 
PROs and Patient Preference Studies
PROs and Patient Preference StudiesPROs and Patient Preference Studies
PROs and Patient Preference StudiesSheily Kamra
 
Gastroenterology Research and Practice Jan16
Gastroenterology Research and Practice Jan16Gastroenterology Research and Practice Jan16
Gastroenterology Research and Practice Jan16Lenka Kellermann
 
cCR TO NACTRT RECTUM-WHAT NEXT?
cCR TO NACTRT RECTUM-WHAT NEXT?cCR TO NACTRT RECTUM-WHAT NEXT?
cCR TO NACTRT RECTUM-WHAT NEXT?Kanhu Charan
 
Chemotherapy of head & neck region /certified fixed orthodontic courses by In...
Chemotherapy of head & neck region /certified fixed orthodontic courses by In...Chemotherapy of head & neck region /certified fixed orthodontic courses by In...
Chemotherapy of head & neck region /certified fixed orthodontic courses by In...Indian dental academy
 
Translation of Orphan DiseaseTrial Design into General Drug Development
Translation of Orphan DiseaseTrial Design into General Drug DevelopmentTranslation of Orphan DiseaseTrial Design into General Drug Development
Translation of Orphan DiseaseTrial Design into General Drug DevelopmentE. Dennis Bashaw
 
ASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENT
ASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENTASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENT
ASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENTKanhu Charan
 
LUNGevity Core Principles of Managing Stage III NSCLC
LUNGevity Core Principles of Managing Stage III NSCLCLUNGevity Core Principles of Managing Stage III NSCLC
LUNGevity Core Principles of Managing Stage III NSCLCGRACEExecDir
 

Mais procurados (20)

Сравнение эффективности препаратов Карбоплатин (Carboplatin) и Паклитаксел (P...
Сравнение эффективности препаратов Карбоплатин (Carboplatin) и Паклитаксел (P...Сравнение эффективности препаратов Карбоплатин (Carboplatin) и Паклитаксел (P...
Сравнение эффективности препаратов Карбоплатин (Carboplatin) и Паклитаксел (P...
 
Journal club
Journal clubJournal club
Journal club
 
Epidemological methods
Epidemological methodsEpidemological methods
Epidemological methods
 
Metformin and cancer journal club
Metformin and cancer  journal clubMetformin and cancer  journal club
Metformin and cancer journal club
 
REIRRADIATION FOR BRAIN TUMORS
REIRRADIATION FOR BRAIN TUMORSREIRRADIATION FOR BRAIN TUMORS
REIRRADIATION FOR BRAIN TUMORS
 
Discuss the principles guiding the use of radiotherapy in surgery
Discuss the principles guiding the use of radiotherapy in surgeryDiscuss the principles guiding the use of radiotherapy in surgery
Discuss the principles guiding the use of radiotherapy in surgery
 
Clinical trials 101
Clinical trials 101Clinical trials 101
Clinical trials 101
 
Managing Oligometastatic Lung Cancer
Managing Oligometastatic Lung CancerManaging Oligometastatic Lung Cancer
Managing Oligometastatic Lung Cancer
 
Umbrella, Basket and Platform trials
Umbrella, Basket and Platform trialsUmbrella, Basket and Platform trials
Umbrella, Basket and Platform trials
 
Innovative clinical trial designs
Innovative clinical trial designs Innovative clinical trial designs
Innovative clinical trial designs
 
Personalized Medicine in Oncology
Personalized Medicine in OncologyPersonalized Medicine in Oncology
Personalized Medicine in Oncology
 
Personalized Medicine in Diagnosis and Treatment of Cancer
Personalized Medicine in Diagnosis and Treatment of Cancer Personalized Medicine in Diagnosis and Treatment of Cancer
Personalized Medicine in Diagnosis and Treatment of Cancer
 
PROs and Patient Preference Studies
PROs and Patient Preference StudiesPROs and Patient Preference Studies
PROs and Patient Preference Studies
 
Gastroenterology Research and Practice Jan16
Gastroenterology Research and Practice Jan16Gastroenterology Research and Practice Jan16
Gastroenterology Research and Practice Jan16
 
cCR TO NACTRT RECTUM-WHAT NEXT?
cCR TO NACTRT RECTUM-WHAT NEXT?cCR TO NACTRT RECTUM-WHAT NEXT?
cCR TO NACTRT RECTUM-WHAT NEXT?
 
Chemotherapy of head & neck region /certified fixed orthodontic courses by In...
Chemotherapy of head & neck region /certified fixed orthodontic courses by In...Chemotherapy of head & neck region /certified fixed orthodontic courses by In...
Chemotherapy of head & neck region /certified fixed orthodontic courses by In...
 
Translation of Orphan DiseaseTrial Design into General Drug Development
Translation of Orphan DiseaseTrial Design into General Drug DevelopmentTranslation of Orphan DiseaseTrial Design into General Drug Development
Translation of Orphan DiseaseTrial Design into General Drug Development
 
ASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENT
ASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENTASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENT
ASCO AND SNO GUIDELINES FOR GLIOMA MANAGEMENT
 
Nutrition in cancer patients dr lokesh 2021 introduction
Nutrition in cancer patients dr lokesh 2021 introductionNutrition in cancer patients dr lokesh 2021 introduction
Nutrition in cancer patients dr lokesh 2021 introduction
 
LUNGevity Core Principles of Managing Stage III NSCLC
LUNGevity Core Principles of Managing Stage III NSCLCLUNGevity Core Principles of Managing Stage III NSCLC
LUNGevity Core Principles of Managing Stage III NSCLC
 

Destaque

Projecte teaming líders mediadors i mediadores
Projecte teaming líders mediadors i mediadoresProjecte teaming líders mediadors i mediadores
Projecte teaming líders mediadors i mediadoreseduardcarrera
 
Janin - Suatu Penghargaan. Suatu Penghayatan.
Janin - Suatu Penghargaan. Suatu Penghayatan.Janin - Suatu Penghargaan. Suatu Penghayatan.
Janin - Suatu Penghargaan. Suatu Penghayatan.Storm Dancer
 

Destaque (7)

El triple filtro
El triple filtroEl triple filtro
El triple filtro
 
Presentación logros
Presentación logrosPresentación logros
Presentación logros
 
Taking Pediatric Oncology outside chennai
Taking Pediatric Oncology outside chennaiTaking Pediatric Oncology outside chennai
Taking Pediatric Oncology outside chennai
 
P001
P001P001
P001
 
Projecte teaming líders mediadors i mediadores
Projecte teaming líders mediadors i mediadoresProjecte teaming líders mediadors i mediadores
Projecte teaming líders mediadors i mediadores
 
Janin - Suatu Penghargaan. Suatu Penghayatan.
Janin - Suatu Penghargaan. Suatu Penghayatan.Janin - Suatu Penghargaan. Suatu Penghayatan.
Janin - Suatu Penghargaan. Suatu Penghayatan.
 
Coches Rchu
Coches RchuCoches Rchu
Coches Rchu
 

Semelhante a Abstract E9911

Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...AnonIshanvi
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...JohnJulie1
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...daranisaha
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...ClinicsofOncology
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...semualkaira
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...semualkaira
 
COO-v1-1016.pdf
COO-v1-1016.pdfCOO-v1-1016.pdf
COO-v1-1016.pdfNainaAnon
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...EditorSara
 
Taxane chemotherapy in ca breast dr.neena john, juniour resident, radiation o...
Taxane chemotherapy in ca breast dr.neena john, juniour resident, radiation o...Taxane chemotherapy in ca breast dr.neena john, juniour resident, radiation o...
Taxane chemotherapy in ca breast dr.neena john, juniour resident, radiation o...Neena John
 
Tamoxifen Therapy in Postmenopausal Iraqi Women with Breast Cancer: Evaluatin...
Tamoxifen Therapy in Postmenopausal Iraqi Women with Breast Cancer: Evaluatin...Tamoxifen Therapy in Postmenopausal Iraqi Women with Breast Cancer: Evaluatin...
Tamoxifen Therapy in Postmenopausal Iraqi Women with Breast Cancer: Evaluatin...semualkaira
 
BALKAN MCO 2011 - E. Vrdoljak - Advanced cervical cancer - what is the gold s...
BALKAN MCO 2011 - E. Vrdoljak - Advanced cervical cancer - what is the gold s...BALKAN MCO 2011 - E. Vrdoljak - Advanced cervical cancer - what is the gold s...
BALKAN MCO 2011 - E. Vrdoljak - Advanced cervical cancer - what is the gold s...European School of Oncology
 
Satyajeet rath chemotherapy and hormone therapy in breast cancer
Satyajeet rath chemotherapy and hormone therapy in breast cancerSatyajeet rath chemotherapy and hormone therapy in breast cancer
Satyajeet rath chemotherapy and hormone therapy in breast cancerSatyajeet Rath
 
Novel Therapies for Cervical Cancer.pdf
Novel Therapies for Cervical Cancer.pdfNovel Therapies for Cervical Cancer.pdf
Novel Therapies for Cervical Cancer.pdfDoriaFang
 
BALKAN MCO 2011 - F. Cardoso - Hormone therapy: best options for pre and post...
BALKAN MCO 2011 - F. Cardoso - Hormone therapy: best options for pre and post...BALKAN MCO 2011 - F. Cardoso - Hormone therapy: best options for pre and post...
BALKAN MCO 2011 - F. Cardoso - Hormone therapy: best options for pre and post...European School of Oncology
 
trials on Chemotherapy in breast cancer
trials on Chemotherapy in breast cancer trials on Chemotherapy in breast cancer
trials on Chemotherapy in breast cancer Dr.Rashmi Yadav
 
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...JohnJulie1
 
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...daranisaha
 
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...semualkaira
 

Semelhante a Abstract E9911 (20)

Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
 
COO-v1-1016.pdf
COO-v1-1016.pdfCOO-v1-1016.pdf
COO-v1-1016.pdf
 
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
Selecting Optimal Regimen in The treatment of Metastatic Triple Negative Brea...
 
Tnbc 2018 update
Tnbc 2018 updateTnbc 2018 update
Tnbc 2018 update
 
Taxane chemotherapy in ca breast dr.neena john, juniour resident, radiation o...
Taxane chemotherapy in ca breast dr.neena john, juniour resident, radiation o...Taxane chemotherapy in ca breast dr.neena john, juniour resident, radiation o...
Taxane chemotherapy in ca breast dr.neena john, juniour resident, radiation o...
 
Tamoxifen Therapy in Postmenopausal Iraqi Women with Breast Cancer: Evaluatin...
Tamoxifen Therapy in Postmenopausal Iraqi Women with Breast Cancer: Evaluatin...Tamoxifen Therapy in Postmenopausal Iraqi Women with Breast Cancer: Evaluatin...
Tamoxifen Therapy in Postmenopausal Iraqi Women with Breast Cancer: Evaluatin...
 
BALKAN MCO 2011 - E. Vrdoljak - Advanced cervical cancer - what is the gold s...
BALKAN MCO 2011 - E. Vrdoljak - Advanced cervical cancer - what is the gold s...BALKAN MCO 2011 - E. Vrdoljak - Advanced cervical cancer - what is the gold s...
BALKAN MCO 2011 - E. Vrdoljak - Advanced cervical cancer - what is the gold s...
 
Satyajeet rath chemotherapy and hormone therapy in breast cancer
Satyajeet rath chemotherapy and hormone therapy in breast cancerSatyajeet rath chemotherapy and hormone therapy in breast cancer
Satyajeet rath chemotherapy and hormone therapy in breast cancer
 
Novel Therapies for Cervical Cancer.pdf
Novel Therapies for Cervical Cancer.pdfNovel Therapies for Cervical Cancer.pdf
Novel Therapies for Cervical Cancer.pdf
 
Ca stomach chemo
Ca stomach chemoCa stomach chemo
Ca stomach chemo
 
BALKAN MCO 2011 - F. Cardoso - Hormone therapy: best options for pre and post...
BALKAN MCO 2011 - F. Cardoso - Hormone therapy: best options for pre and post...BALKAN MCO 2011 - F. Cardoso - Hormone therapy: best options for pre and post...
BALKAN MCO 2011 - F. Cardoso - Hormone therapy: best options for pre and post...
 
trials on Chemotherapy in breast cancer
trials on Chemotherapy in breast cancer trials on Chemotherapy in breast cancer
trials on Chemotherapy in breast cancer
 
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
 
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
 
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a R...
 

Abstract E9911

  • 1. Result Content View Page 1 of 1 [48] Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. From the Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG), Cancer and Acute Leukemia Group B (CALBG), and the North Central Cancer Treatment Group (NCCTG) Purpose: To compare the effectiveness of adjuvant paclitaxel with docetaxel, and the effectiveness of every 3 week with weekly adjuvant taxane therapy in patients with operable breast cancer. Methods: Eligibility criteria included axillary lymph node positive or high-risk (tumor at least 2 cm) node-negative breast cancer. All patients received 4 cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) every 3 weeks, followed by either: (1) paclitaxel 175 mg/m2 every 3 weeks x 4 (P3), (2) paclitaxel 80 mg/m2 weekly x 12 (P1), (3) docetaxel 100 mg/m2 every 3 weeks x 4 (D3), or (4) docetaxel 35 mg/m2 weekly x 12 (D1). All patients with estrogen and/or progesterone receptor (ER/PR)-positive disease received a 5 year or longer course of adjuvant hormonal therapy, consisting either of tamoxifen (20 mg daily), an aromatase inhibitor (AI; for post-menopausal women beginning in 2003 at the discretion of the treating physician), or tamoxifen followed by an AI. The primary comparisons included taxane (P vs. D) and schedule (every 3 weeks vs. weekly). The trial had 86% power to detect a 17.5% reduction in failure for either primary comparison. The primary endpoint was disease-free survival (DFS), defined as local, regional, and/or distant relapse, second primary breast cancer, or death without recurrence. Results: A total of 4988 eligible patients were accrued between October 1999 and January 2002. The ECOG Data Monitoring Committee advised release of the data after 856 DFS events (82% of total information) occurred after a median follow-up was 46.5 months at the fourth planned interim analysis, including the following number of DFS events (and relapses) for each arm: P3-230 (197), P1-195 (168), D3-206 (163), D1-225 (185). For the primary analyses, there were no significant differences in the hazard ratios (HR) comparing taxane (0.985; p=0.83) or schedule (1.043; p=0.54) for DFS, and it is unlikely that either comparison could become significant after full planned information is obtained. When comparing the standard arm (P3) to the other arms (with a HR > 1 favoring the experimental arms), the HRs were 1.20 (95% confidence intervals [CI] 0.99, 1.46; p = 0.06) for arm P1, 1.13 (95% CI 0.94, 1.36; p=0.20) for arm D3, and 1.03 (95% CI 0.85, 1.23; p=0.78) for arm D1. The incidence of worst grade toxicity (grade 3/4) was 24%/6% for arm P3, 24%/4% for arm P1, 21%50% for arm D3, and 39%/6% for arm D1. Conclusions: There were no differences in DFS when comparing taxane or schedule, the primary study endpoints. There was a trend toward improved DFS associated with weekly paclitaxel compared with the standard treatment arm. Thursday, December 8, 2005 3:30 PM General Session 2 (1:30 PM-3:30 PM) Close Window http://www.abstracts2view.com/sabcs05/view.php?nu=SABCS05L_2020 1/4/2006 PDF created with FinePrint pdfFactory Pro trial version www.pdffactory.com